Overview of Dr. Goldberg
Dr. Aaron Goldberg is a hematologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Weill Cornell Medicine and has been in practice 7 years. He is one of 61 doctors at Memorial Sloan Kettering Cancer Center who specialize in Hematology. He has more than 50 publications and over 500 citings.
Office
530 East 74th Street
New York, NY 10021Fax+1 929-321-8153
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
Brigham and Women's HospitalResidency, Internal Medicine, 2011 - 2014
Weill Cornell MedicineClass of 2011, MD
Rockefeller UniversityPhD, Epigenetics and Chromatin Biology, 2004 - 2010
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 2014 - 2026
NJ State Medical License 2018 - 2025
NC State Medical License 2020 - 2022
ME State Medical License 2020 - 2021
MA State Medical License 2014 - 2015- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- ASH Fellow Scholar Award in Clinical Research American Society of Hematology, 2018
- ASCO Young Investigator Award Conquer Cancer Foundation of the American Society of Clinical Oncology, 2017
- Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Oncology/Hematology Clinical Research Award Pfizer, 2017
- Join now to see all
Clinical Trials
- Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL) Start of enrollment: 2016 Feb 01
- Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Start of enrollment: 2018 Aug 15
- Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD) Start of enrollment: 2018 Oct 03
- Join now to see all
Publications & Presentations
PubMed
- 1521 citationsEpigenetics: A Landscape Takes ShapeAaron D Goldberg, C. David Allis, Emily Bernstein
Cell. 2007-02-23 - 951 citationsDistinct Factors Control Histone Variant H3.3 Localization at Specific Genomic RegionsAaron D Goldberg, Laura A. Banaszynski, Kyung-Min Noh, Peter W. Lewis, Simon J. Elsaesser
Cell. 2010-03-05 - 109 citationsClinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AMLMaximilian Stahl, Kamal Menghrajani, Andriy Derkach, Alexander Chan, Wenbin Xiao
Blood Advances. 2021-03-09
Abstracts/Posters
- Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing...Aaron D Goldberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leu...Aaron D Goldberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction ChemotherapyAaron D Goldberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co- Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Loss of Plasmacytoid Dendritic Cell Differentiation Is Highly Predictive for Persistent Measurable Residual Disease and Poor Outcomes in Acute Myeloid Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
